The State of Heart Failure Care in Canada: Minimal Improvement in Readmissions Over Time Despite an Increased Number of Evidence-Based Therapies
Authors:
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
- Novartis Pharmaceuticals Canada Inc
- Servier
- Novartis
- Abbott Canada
- Pfizer
- Sanofi
- Canadian Cardiovascular Society
- AstraZeneca
- Medtronic
- Takeda Canada
- Bayer
- Boehringer Ingelheim
- American Regent
- Amgen
- Boston Scientific Corporation
- Otsuka America
- Merck
- Abbott Laboratories
- Johnson and Johnson
This publication has 33 references indexed in Scilit:
- Relation of Acute Heart Failure Hospital Length of Stay to Subsequent Readmission and All-Cause MortalityThe American Journal of Cardiology, 2015
- In-hospital treatment and outcomes of heart failure in specialist and non-specialist services: a retrospective cohort study in the elderlyOpen Heart, 2015
- Length of Hospital Stay and 30-Day Readmission Following Heart Failure Hospitalization: Insights from the EVEREST TrialEuropean Journal of Heart Failure, 2015
- Transitional Care Interventions to Prevent Readmissions for Persons With Heart FailureAnnals of Internal Medicine, 2014
- Practice-Level Variation in Use of Recommended Medications Among Outpatients With Heart FailureCirculation: Heart Failure, 2013
- The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Acute and Chronic Heart FailureCanadian Journal of Cardiology, 2013
- Treatment and Risk in Heart FailureCirculation: Cardiovascular Quality and Outcomes, 2010
- Hospitalizations in Patients With Heart Failure: Who and WhyJACC, 2009
- Risk-Treatment Mismatch in the Pharmacotherapy of Heart FailureJAMA, 2005
- Differences in generalist and specialist physicians’ knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failureJournal of General Internal Medicine, 1997